The European Patent Office (EPO) has published a patent application, EP2026030528A1, related to activated hepatocyte growth factor. The application was published on March 18, 2026, and includes various IPC classifications relevant to biotechnology and protein chemistry. Notably, the designation of inventors has not yet been filed.

This publication represents a new patent application filing. While it does not impose immediate compliance obligations on regulated entities, it is relevant for companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in research and development of growth factors. Companies should monitor the progress of this application through the EPO patent process.